FDA urges genetic test before using Glaxo AIDS drug By Lisa Richwine WASHINGTON (Reuters) - AIDS patients should have a genetic test before treatment with GlaxoSmithKline Plc's drug Ziagen to see whether they face a higher risk of a potentially fatal reaction, U.S.regulators said on...
UPDATE 1-US urges genetic test before using Glaxo AIDS drug WASHINGTON, July 24 (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research, Stock Buzz)(GSK.N: Quote, Profile, Research, Stock Buzz) drug, Ziagen, to see if...
U.S. urges genetic test before using Glaxo AIDS drug For patients who test positive for a specific gene variation, Ziagen treatment 'is not recommended and should be considered only under exceptional circumstances when the potential benefit outweighs the risk,' the Food and Drug...
U.S. urges genetic test before using Glaxo AIDS drug WASHINGTON (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline's drug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, U.S.regulators said on Thursday.
For...
FDA urges genetic test before using Glaxo AIDS drug WASHINGTON (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline Plc's drug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, U.S.regulators said on Thursday.
For...
FDA urges genetic test before using Glaxo AIDS drug WASHINGTON (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline Plc's drug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, U.S.regulators said on Thursday.
For...
FDA urges genetic test before using Glaxo AIDS drug WASHINGTON (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline Plc's drug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, U.S.regulators said on Thursday.
For...
US urges genetic test before using Glaxo AIDS drug WASHINGTON (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline (nyse: GSK - news - people ) Plc'sdrug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, U.S.
FDA Announces Important Safety-Related Label Update for Ziagen (abacavir sulfate) FDA approved changes to the package insert for Ziagen (abacavir sulfate) highlighting information about the association of the HLA-B*5701 allele (a part of a gene) and hypersensitivity reactions (HSR) caused by abacavir-containing...
Allergy Testing, Heart Risk Assessment Recommended Before Starting Abacavir All HIV-positive people considering an antiretroviral regimen that contains abacavirthe active component in Ziagen and also found in Epzicom and Trizivirshould first be tested for a human gene that has been closely tied to a serious...
FDA urges genetic test with Glaxo AIDS drug WASHINGTON (Reuters) - AIDS patients should be tested before treatment with GlaxoSmithKline Plc's AIDS drug Ziagen for a genetic variant that raises the risk of a potentially fatal reaction, U.S.regulators said on Thursday.
For...
US urges genetic test with Glaxo AIDS drug WASHINGTON, July 24 (Reuters) - AIDS patients should be tested before treatment with GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research, Stock Buzz)(GSK.N: Quote, Profile, Research, Stock Buzz) AIDS drug Ziagen for a genetic...
FDA urges genetic test with Glaxo AIDS drug For patients who test positive for the variation, Ziagen treatment 'is not recommended and should be considered only under exceptional circumstances when the po FDA urges genetic test with Glaxo AIDS drug.
US urges genetic test with Glaxo AIDS drug (Reuters) - AIDS patients should be tested before treatment with GlaxoSmithKline Plc's AIDS drug Ziagen for a genetic variant that raises the risk of a potentially fatal reaction, U.S.regulators said on Thursday.
US urges genetic...
F.D.A. Urges Genetic Test Before Giving AIDS Drug Abacavir, developed by GlaxoSmithKline, is sold under the name Ziagen. It is also a component of two combination pills Trizivir and Epzicom.
The recommendation for the test is part of a movement toward so-called personalized...
FDA urges genetic test before giving AIDS drug Seeking to prevent life-threatening side effects, the Food and Drug Administration is urging doctors to use a genetic test to screen patients before prescribing a drug widely used for HIV infection and AIDS.In an advisory it is expected...
F.D.A. Urges Genetic Test Before Giving AIDS Drug Seeking to prevent life-threatening side effects, the Food and Drug Administration is urging doctors to use a genetic test to screen patients before prescribing a drug widely used for H.I.V.infection and AIDS.
In an advisory it is...
F.D.A. Urges Genetic Test Before Giving AIDS Drug Seeking to prevent life-threatening side effects, the is urging doctors to use a genetic test to screen patients before prescribing a drug widely used for H.I.V.infection and AIDS.
In an advisory it is expected to issue Thursday, the...
FDA Announces Important Safety-Related Label Update for Ziagen (abacavir sulfate) FDA approved changes to the package insert for Ziagen (abacavir sulfate) highlighting information about the association of the HLA-B*5701 allele (a part of a gene) and hypersensitivity reactions (HSR) caused by abacavir-containing...
Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear Healthcare workers and patients need to be vigilant about the possibility of an allergic reaction after starting abacavir (Ziagen), even if the HLA-B*5701 screening test is negative, emphasise investigators in separate reports in the...
Earnings Preview: Gilead Sciences OVERVIEW: Demand for the company's HIV treatments remains strong, based on sales estimates from IMS Health during the quarter.Gilead gets most of its revenue from Truvada, which is a mix of its Viread and Emtriva treatments, and Atripla,...
Earnings Preview: Gilead Sciences OVERVIEW: Demand for the company's HIV treatments remains strong, based on sales estimates from IMS Health during the quarter.Gilead gets most of its revenue from Truvada, which is a mix of its Viread and Emtriva treatments, and Atripla,...
Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist MELBOURNE, Australia Based in California, USA Holding a Ph.D.in Microbiology and Immunology, Dr.
Averett has authored or coauthored over 40 peer-reviewed publications and numerous presentations.
He is an inventor on 17 issued and nine...
Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist US Office Relocation to California MELBOURNE, Australia, July 10, 2008 /PRNewswire/ -- Cytopia announced today the appointment of Dr.Devron Averett as Chief Scientific Advisor to the company.
Based in California, USA, Dr.
Averett will...
Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist MELBOURNE, Australia, July 10 /PRNewswire/ -- Cytopia announced today the appointment of Dr.Devron Averett as Chief Scientific Advisor to the company.
Based in California, USA, Dr.
Averett will work closely with the company's...
